- Algernon (AGN) has treated the last patient in its phase 2 study of idiopathic pulmonary fibrosis (IPF) and chronic cough
- The company estimates that topline data will be available in July 2022
- It remains optimistic about Ifenprodil’s functionality compared to current treatments for the conditions
- Algernon investigates safe, approved drugs for new disease applications
- Algernon (AGN) is up by 10.35 per cent trading at $5.65 per share
Algernon (AGN) has treated the last patient in its phase 2 study of IPF and chronic cough.
The company estimates that topline data will be available in July 2022.
Phase 2 study summary
The study is seeking to establish proof of concept for NP-120 (Ifenprodil) for IPF and chronic cough.
It includes 20 patients with an IPF diagnosis and a self-described moderate or worse cough.
Patients were treated with Ifenprodil (20 mg TID) for 12 weeks.
The primary endpoint of the IPF part of the study is the proportion of patients who achieve zero reduction in lung function at 12 weeks against the baseline.
The primary endpoint for the chronic cough portion is a 50-per-cent reduction in average 24-hour cough count at 12 weeks against the baseline.
IPF prognosis remains poor overall, with 50-per-cent mortality expected within 3-4 years.
The company has filed global intellectual property rights for Ifenprodil for the treatment of respiratory diseases.
“We are pleased to be coming closer to this value inflection point in our phase 2 clinical trial for IPF and chronic cough, both debilitating conditions with limited treatment options,” said Christopher J. Moreau, Algernon’s CEO. “We believe Ifenprodil has a unique mechanism of action when compared to the current standard of care for IPF and the drugs in development for chronic cough.”
Algernon is a drug repurposing company that investigates safe, approved drugs for new disease applications.
Algernon (AGN) is up by 10.35 per cent trading at $5.65 per share as of 11:37 am EST.
